#CheckpointInhibitor

Live, measured metrics for the hashtag #CheckpointInhibitor from the open social web. Every number carries a named source and the time it was fetched. Nothing is estimated.

hashtag.org network · sponsored

Own #checkpointinhibitor

This #name is available to claim. It becomes your portal on the open agent web: this very page, a keyword you rank for by an open public stake, and a verifiable identity for AI agents. Nobody else sells a page like this for every #name.

$5.00/ year · 19-character #name
Claim #checkpointinhibitor — $5.00/yr→Buy on hashtag.space (web3)
card via hashtag.org · tokens via hashtag.space
0
Uses / 7 days
Mastodon
0
Accounts / 7 days
Mastodon
8
Recent posts
Mastodon
~0/hr
Recent pace
Mastodon · last 8
0
Avg reactions / post
Mastodon · last 8

Day-by-day usage

measured · fosstodon.org (Mastodon public tags API) · fetched 2026-07-30 08:01 UTC
0
07-24
0
07-25
0
07-26
0
07-27
0
07-28
0
07-29
0
07-30

0 uses by 0 unique accounts across the window. Real per-day counts, not estimates. Newest bar is today so far.

Related hashtags

measured · fosstodon.org (Mastodon public search API) · fetched 2026-07-30 08:01 UTC

No related tags with measured usage found for #checkpointinhibitor.

Live pulse

measured · fosstodon.org (Mastodon tag timeline) · fetched 2026-07-30 08:01 UTC

Everything below is measured over the latest 8 public posts (spanning ~19514 hours).

Posting hours (UTC)

00:0012:0023:00

Languages: English (7) · French (1)

Avg boosts / post: 2.4

Top of the latest posts

  • Improving Ovarian Cancer Immunotherapy: Cancer immunologists at the University of Virginia have now discovered what underlies this failure. #immunotherapy #checkpointinhibitor #ovarian #cancer #biome #flagellin https://www.instagram.com/ree

    Howard Smith MD, AM@[email protected]♥ 0↻ 12025-03-11 12:38 UTCView post →

  • This one is for adults with primary advanced or recurrent endometrial cancer. "This new approval is based on data from the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868. Results reported last year in the New England Journal of Medicine

    Thiago Carvalho@[email protected]♥ 0↻ 02024-06-22 17:04 UTCView post →

  • "Novartis’ anti-TIM-3 antibody has flunked a phase 3 blood cancer trial, prompting the Swiss drugmaker to pull the drug candidate from its pipeline. The failed study was the biggest test to date of an immuno-oncology target into which a who

    Thiago Carvalho@[email protected]♥ 0↻ 22024-02-01 14:36 UTCView post →

Every number above is measured from a named public API at the shown fetch time. Nothing is estimated or extrapolated. Platforms that lock their data behind paid APIs are not shown. Agents: the same numbers, as JSON, at /api/hashtags/checkpointinhibitor